There are no new names in our Top 20 Pharma ranks, but mega-mergers and patent expirations have re-shaped the upper end the list this year. Pfizer stayed on top for another year (although it may choose to abdicate), but Novartis creeped up from #3 to #2, boosted by its Alcon revenues, and Merck jumped from #6 to #3 after integrating Schering-Plough’s sales. Sanofi and GlaxoSmithKline, meanwhile, both fell behind as their annual sales dropped from 2009. (Good thing Sanofi will be able to add in some Genzyme revenues next year!)
Pharma is in the midst of some tumultuous times. I foresee a lot more jockeying for position in the next several years.
—Gil Y. Roth
Editor
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth
Top 20 Pharmas
based on 2010 revenues, in millions
| 1 | Pfizer |
$58,523 |
| 2 |
$44,420 |
|
| 3 |
$39,811 |
|
| 4 |
$37,403 |
|
| 5 |
$36,156 |
|
| 6 |
$32,515 |
|
| 7 |
$22,396 |
|
| 8 |
$21,685 |
|
| 9 |
$19,894 |
|
| 10 |
$19,484 |
|
| 11 |
$16,121 |
|
| 12 |
$14,829 |
|
| 13 |
$14,485 |
|
| 14 |
$12,883 |
|
| 15 |
$11,161 |
|
| 16 |
$10,794 |
|
| 17 |
$8,542 |
|
| 18 |
$8,440 |
|
| 19 |
$7,390 |
|
| 20 |
$5,404 |
